|
US6361796B1
(en)
*
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
|
US20050119237A1
(en)
*
|
1999-06-18 |
2005-06-02 |
Ramot University Authority For Applied Research & Industrial Development Ltd. |
Non-malignant disease treatment with Ras antagonists
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
CN1187052C
(zh)
|
2000-03-30 |
2005-02-02 |
布里斯托尔-迈尔斯斯奎布公司 |
含有司他夫定(stavudine)的持续释放微球
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
|
US6720000B2
(en)
*
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
|
DE10137102A1
(de)
*
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
|
US20040001886A1
(en)
*
|
2001-10-17 |
2004-01-01 |
Dr. Reddy's Laboratories Limited |
Stabilized pharmaceutical formulations containing amlodipine maleate
|
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
|
US6602911B2
(en)
*
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
|
US20030175346A1
(en)
*
|
2002-02-01 |
2003-09-18 |
Anne Billotte |
Osmotic delivery system
|
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
|
WO2003096968A2
(en)
*
|
2002-05-15 |
2003-11-27 |
Sun Pharmaceutical Industries Limited |
Oral osmotic controlled drug delivery system
|
|
US20040033257A1
(en)
*
|
2002-05-30 |
2004-02-19 |
Strides Inc. |
Pharmaceutical formulation in a drug delivery system and process for preparing the same
|
|
WO2004026261A2
(en)
*
|
2002-09-19 |
2004-04-01 |
Three Rivers Pharmaceuticals, Llc |
Composition containing ribavirin and use thereof
|
|
US7538094B2
(en)
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
WO2004069187A2
(en)
*
|
2003-02-03 |
2004-08-19 |
Shire Laboratories, Inc. |
Drug formulation and delivery using crystalline methylated cyclodextrins
|
|
CN101265226B
(zh)
|
2003-05-22 |
2013-04-24 |
联合治疗公司 |
化合物和释放前列环素类似物的方法
|
|
PT1558582E
(pt)
|
2003-07-22 |
2006-05-31 |
Arena Pharm Inc |
Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
|
|
US7611728B2
(en)
*
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
|
WO2005072705A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
|
US7776358B2
(en)
*
|
2004-07-22 |
2010-08-17 |
Synthon Ip Inc. |
Extended release venlafaxine besylate tablets
|
|
US7619007B2
(en)
*
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
|
US8389578B2
(en)
|
2004-11-24 |
2013-03-05 |
Adamas Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
|
US8252331B2
(en)
*
|
2004-12-03 |
2012-08-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
US8574626B2
(en)
|
2004-12-03 |
2013-11-05 |
Osmotica Kereskedelmi és Szolgáltató KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
US8128952B2
(en)
*
|
2005-01-12 |
2012-03-06 |
Clemson University Research Foundation |
Ligand-mediated controlled drug delivery
|
|
KR20070102563A
(ko)
*
|
2005-01-26 |
2007-10-18 |
엘란 파마 인터내셔널 리미티드 |
정신병치료제를 함유하는 조절방출형 조성물
|
|
WO2006088864A1
(en)
*
|
2005-02-16 |
2006-08-24 |
Elan Pharma International Limited |
Controlled release compositions comprising levetiracetam
|
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
|
CA2598288A1
(en)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of heterocyclic amide derivatives
|
|
US8778979B2
(en)
|
2005-04-05 |
2014-07-15 |
Yale University |
Glutamate agents in the treatment of mental disorders
|
|
JP5666087B2
(ja)
|
2005-04-06 |
2015-02-12 |
アダマス・ファーマシューティカルズ・インコーポレーテッド |
Ｃｎｓ関連疾患の治療のための方法及び組成物
|
|
EP1874271A4
(en)
*
|
2005-04-12 |
2012-01-25 |
Elan Pharma Int Ltd |
COMPOSITIONS WITH MODIFIED RELEASE FROM A FLUOROCYTIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
|
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
US20090099031A1
(en)
*
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
EP1929073A4
(en)
*
|
2005-09-27 |
2010-03-10 |
Amunix Inc |
PROTEIN MEDICAMENT AND ITS USE
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US8440695B2
(en)
*
|
2005-11-09 |
2013-05-14 |
St Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
|
JP5738516B2
(ja)
|
2005-12-30 |
2015-06-24 |
ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド |
心機能改善のためのニューレグリンの徐放
|
|
US8747897B2
(en)
|
2006-04-27 |
2014-06-10 |
Supernus Pharmaceuticals, Inc. |
Osmotic drug delivery system
|
|
US8124598B2
(en)
*
|
2006-09-14 |
2012-02-28 |
Sharon Sageman |
7-keto DHEA for psychiatric use
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
WO2009023253A2
(en)
|
2007-08-15 |
2009-02-19 |
Arena Pharmaceuticals Inc. |
IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
|
|
US8933197B2
(en)
*
|
2007-08-15 |
2015-01-13 |
Amunix Operating Inc. |
Compositions comprising modified biologically active polypeptides
|
|
US20100160274A1
(en)
*
|
2007-09-07 |
2010-06-24 |
Sharon Sageman |
7-KETO DHEA for Psychiatric Use
|
|
KR20160048222A
(ko)
|
2007-12-17 |
2016-05-03 |
유나이티드 세러퓨틱스 코오포레이션 |
레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
|
EP2331088A4
(en)
|
2008-08-06 |
2011-10-12 |
Gosforth Ct Holdings Pty Ltd |
COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
|
|
CN104739829B
(zh)
|
2008-10-28 |
2018-11-06 |
艾尼纳制药公司 |
用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
RU2589823C2
(ru)
*
|
2009-04-09 |
2016-07-10 |
Алкермес Фарма Айэленд Лимитед |
Композиция для доставки лекарственных средств
|
|
JP5839597B2
(ja)
|
2009-06-08 |
2016-01-06 |
アムニクス オペレーティング インコーポレイテッド |
グルコース調節ポリペプチド並びにその作成及び使用方法
|
|
SI2440241T1
(sl)
|
2009-06-08 |
2017-11-30 |
Amunix Operating Inc. |
Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
|
|
AU2010290131C1
(en)
|
2009-08-24 |
2015-12-03 |
Amunix Operating Inc. |
Coagulation factor VII compositions and methods of making and using same
|
|
MX365650B
(es)
|
2009-12-02 |
2019-06-10 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
|
CA2864126A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
BR112014020694A2
(pt)
|
2012-02-15 |
2018-05-08 |
Amunix Operating Inc. |
proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
|
|
EP2869911A4
(en)
|
2012-07-09 |
2016-05-11 |
Fosmo Med Inc |
DEVICES WITH MEMBRANE-EDUCED FORWARD OSMOSIS
|
|
ES2821528T3
(es)
|
2012-11-14 |
2021-04-26 |
Grace W R & Co |
Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
|
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US20150133516A1
(en)
|
2013-11-13 |
2015-05-14 |
Brian K. Adams |
Methods and Compositions for Treating ADHD
|
|
CA2959660A1
(en)
|
2014-09-03 |
2016-03-10 |
Genesegues, Inc. |
Therapeutic nanoparticles and related compositions, methods, and systems
|
|
ES2778274T3
(es)
|
2014-10-20 |
2020-08-10 |
United Therapeutics Corp |
Síntesis de productos intermedios para producir derivados de prostaciclina
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
US20180362974A1
(en)
|
2015-07-02 |
2018-12-20 |
University Of Louisville Research Foundation, Inc. |
EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
BR112018002150A2
(pt)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
|
|
IL319473A
(en)
|
2016-12-02 |
2025-05-01 |
Bioverativ Therapeutics Inc |
Methods for treating hemophilic arthritis using chimeric blood clotting factors
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
US20190247331A1
(en)
|
2018-02-15 |
2019-08-15 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|
|
US10213394B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|
|
US10213393B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság |
Composition and method for treating neurological disease
|
|
BR112020022164A2
(pt)
|
2018-05-18 |
2021-02-02 |
Bioverativ Therapeutics Inc. |
métodos de tratamento de hemofilia a
|
|
JP2023531494A
(ja)
|
2020-06-25 |
2023-07-24 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
Ｈｅｒ－２標的化二重特異性組成物ならびにその作製および使用のための方法
|
|
US20250049743A1
(en)
|
2023-08-08 |
2025-02-13 |
United Therapeutics Corporation |
Method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same
|